

Richard J Gralla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1419525/publications.pdf>

Version: 2024-02-01

53
papers

3,441
citations

331670

21
h-index

206112

48
g-index

54
all docs

54
docs citations

54
times ranked

3702
citing authors

#	ARTICLE	IF	CITATIONS
1	Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation. <i>Oncologist</i> , 2021, 26, 224-230.	3.7	2
2	The impact of smoking on the effectiveness of immune checkpoint inhibitors – a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 96-100.	1.8	13
3	Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy. <i>Oncologist</i> , 2020, 25, e589-e597.	3.7	21
4	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.	2.4	4
5	Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 164-186.	4.4	2
6	Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma. <i>Clinical Lung Cancer</i> , 2019, 20, e242-e246.	2.6	25
7	Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT). <i>Supportive Care in Cancer</i> , 2018, 26, 2353-2359.	2.2	34
8	Content validity and electronic PRO (ePRO) usability of the Lung Cancer Symptom Scale-Mesothelioma (LCSS-Meso) in mesothelioma patients. <i>Supportive Care in Cancer</i> , 2018, 26, 2229-2238.	2.2	11
9	Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 194-204.	1.1	85
10	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 210.	7.1	437
11	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 792-800.	1.1	17
12	Radiation therapy and delayed emesis. <i>Annals of Palliative Medicine</i> , 2018, 7, 479-480.	1.2	0
13	Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. <i>Supportive Care in Cancer</i> , 2017, 25, 1661-1671.	2.2	37
14	Key issues affecting quality of life and patient-reported outcomes in prostate cancer: an analysis conducted in 2128 patients with initial psychometric assessment of the prostate cancer symptom scale (PCSS). <i>BMJ Supportive and Palliative Care</i> , 2017, 7, bmjspcare-2016-001146.	1.6	4
15	Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron, in older patients. <i>Journal of Geriatric Oncology</i> , 2017, 8, 56-63.	1.0	7
16	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	196
17	Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. <i>Cancer Medicine</i> , 2017, 6, 723-729.	2.8	23
18	Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 633-643.	1.1	122

#	ARTICLE	IF	CITATIONS
19	2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. <i>Supportive Care in Cancer</i> , 2017, 25, 271-275.	2.2	36
20	2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following moderately emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2017, 25, 289-294.	2.2	54
21	Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). <i>Current Oncology Reports</i> , 2016, 18, 37.	4.0	128
22	Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program. <i>Oncologist</i> , 2016, 21, 494-502.	3.7	15
23	Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. <i>Supportive Care in Cancer</i> , 2016, 24, 4617-4625.	2.2	18
24	The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. <i>Journal of Thoracic Oncology</i> , 2016, 11, 808-818.	1.1	20
25	Economic, Transfusion, and Efficacy Outcomes with the Addition of IV Iron Sucrose to Oral Iron Therapy in Pregnancy Associated Iron Deficiency Anemia. <i>Blood</i> , 2016, 128, 4737-4737.	1.4	0
26	Quality of life evaluation in cancer: The past and the future. <i>Cancer</i> , 2015, 121, 4276-4278.	4.1	3
27	Anti-emetics in paediatric patients receiving chemotherapy. <i>Lancet Oncology</i> , The, 2015, 16, 351-353.	10.7	2
28	Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority phase 3 trial. <i>Supportive Care in Cancer</i> , 2015, 23, 723-732.	2.2	36
29	Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria. <i>Future Oncology</i> , 2015, 11, 2541-2551.	2.4	13
30	Preferences for Cancer Support Group Topics and Group Satisfaction Among Patients and Caregivers. <i>Journal of Psychosocial Oncology</i> , 2014, 32, 112-123.	1.2	11
31	Acquired Von Willebrand's Syndrome in Systemic Lupus Erythematosus. <i>Case Reports in Hematology</i> , 2014, 2014, 1-7.	0.4	3
32	An Evidence-Based Determination of Issues Affecting Quality of Life and Patient-Reported Outcomes in Lung Cancer: Results of a Survey of 660 Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1243-1248.	1.1	52
33	Enhancing accurate prediction of survival outcomes and aiding decision making in malignant pleural mesothelioma (MPM) using a three-item index from the LCSS-meso PRO measure: Results from a randomized 444 patient (pt) prospective trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7588-7588.	1.6	3
34	Improving clinical prognostic categories beyond performance status: Enhancing accuracy in survival prediction with a three-item patient-reported outcome (PRO) index from the LCSS in lung cancer and mesothelioma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8065-8065.	1.6	2
35	A prospective, randomized, double-blind phase 3 trial of extended-release granisetron (APF530) versus palonosetron (PALO) for preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately (MEC) or highly (HEC) emetogenic chemotherapy: Does a reanalysis using newer ASCO emetogenicity criteria affect study conclusions?. <i>Journal of Clinical Oncology</i> , 2014, 32, 9648-9648.	1.6	1
36	COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS7611-TPS7611.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Medical and socioeconomic factors associated with triple-negative breast cancer (TNBC) in women with health care disparities.. Journal of Clinical Oncology, 2014, 32, e17512-e17512.	1.6	0
38	Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL). Supportive Care in Cancer, 2013, 21, 165-172.	2.2	31
39	A theory-based decision aid for patients with cancer: results of feasibility and acceptability testing of DecisionKEYS for cancer. Supportive Care in Cancer, 2013, 21, 889-899.	2.2	20
40	Prediction of survival outcomes in NSCLC using a new PRO index from the LCSS (Lung Cancer Symptom) Tj ETQq0 0,0 rgBT /Qverlock 1	1.6	0
41	Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).. Journal of Clinical Oncology, 2013, 31, 9512-9512.	1.6	3
42	NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting (CINV) following repeated chemotherapy cycles: Results of a phase III trial.. Journal of Clinical Oncology, 2013, 31, e20716-e20716.	1.6	1
43	Overcoming health care disparities in cancer treatment by instituting a patient navigation program.. Journal of Clinical Oncology, 2013, 31, TPS6644-TPS6644.	1.6	0
44	Overcoming barriers in incorporating evaluation of quality of life (QL) and symptoms by using the ePRO version of the LCSS (eLCSS-QL) in a large-scale multinational NSCLC trial (AP-QL Trial).. Journal of Clinical Oncology, 2013, 31, 8092-8092.	1.6	1
45	Baseline characteristics from two ongoing phase III trials for the prevention and treatment of muscle wasting in NSCLC.. Journal of Clinical Oncology, 2013, 31, e19100-e19100.	1.6	0
46	Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Supportive Care in Cancer, 2011, 19, 57-62.	2.2	28
47	Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS). Supportive Care in Cancer, 2009, 17, 307-313.	2.2	21
48	Delayed emesis: moderately emetogenic chemotherapy. Supportive Care in Cancer, 2005, 13, 104-108.	2.2	64
49	Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy. Journal of Clinical Oncology, 2005, 23, 2822-2830.	1.6	418
50	The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatinâ€”The Aprepitant Protocol 052 Study Group. Journal of Clinical Oncology, 2003, 21, 4112-4119.	1.6	725
51	Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Supportive Care in Cancer, 1999, 7, 140-148.	2.2	105
52	Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1â€”Receptor Antagonist. New England Journal of Medicine, 1999, 340, 190-195.	27.0	372
53	Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale. Cancer, 1994, 73, 2087-2098.	4.1	211